SALA DE IMPRENSA
20487_FP_Header_Newsroom_Website_2400x900px

As últimas notícias da Dr. Falk Pharma

Bem-vindo à nossa Sala de Imprensa que fornece as últimas notícias, comunicados de imprensa, anúncios de ensaios clínicos, eventos e muito mais da Dr. Falk Pharma.

Siga-nos no LinkedIn!

Evento

EASL 2024

15.05.2024

From 5-8 June 2024 in Milan - we look forward to seeing you (exhibition space E2)

Saber mais

Comunicado de Imprensa

FDA clearance of IND application for naronapride

27.03.2024

...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US

Saber mais

Institucional

Hoje é o Dia das Doenças Raras

29.02.2024

Já ouviu falar de EoE, CBP ou CEP?

Saber mais

Comunicado de Imprensa

Advancing the development of naronapride...

07.02.2024

...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication

Saber mais

Evento

ECCO 2024

29.01.2024

Satellite Symposium "Navigating Ulcerative Proctitis" on 23.02.2024

Saber mais

Institucional

Feliz Natal

21.12.2023

...e boas festas

Saber mais

Institucional

Parcerias

18.10.2023

Sobre nós e nossos Innovation Champions

Saber mais

Institucional

Moonshot Thinking

11.10.2023

An evening with Daniel Cronin and lots of ideas!

Saber mais

Institucional, Indicações

Hoje é o Dia Mundial da DII!

19.05.2023

Teste os seus conhecimentos e saiba mais sobre a DII

Saber mais

Institucional, Indicações

Rare Disease Day

28.02.2023

As the experts in digestive and metabolic medicine, our focus is also on rare diseases.

Saber mais

Institucional, Evento

ECCO Congress 2023

22.02.2023

In Copenhagen, Denmark, from March 1 – 4, 2023.

Saber mais

Institucional

3000 LinkedIn-Followers!

17.02.2023

Thank you very much!
Together we know more. Together we do more.

Saber mais

Institucional, Comunicado de Imprensa

Initiation of Phase II Study of naronapride in patients with gastroparesis

15.02.2023

Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated

Saber mais

Institucional

Merry Christmas

22.12.2022

We wish you happy holidays and all the best for 2023

Saber mais

Institucional

New Work in Freiburg

14.12.2022

Pilot space to find out which elements & spaces work for us

Saber mais

Institucional, Comunicado de Imprensa

Collaboration and Licensing Agreement with Takeda and Zedira

20.10.2022

To Develop First-in-Class Celiac Disease Therapy

Saber mais

Logo UEG Week
Evento

UEG Week 2022

19.09.2022

Join us from October 8 – 11 in Vienna on booth no. 43 or virtually!

Saber mais

Logo Zedira
Comunicado de Imprensa, Estudo

NAFLD: Phase 2a proof of concept study of ZED1227

01.07.2022

Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.

Saber mais

Evento

International Liver Congress™ in London

03.06.2022

We are proud to be a sponsor and look forward to seeing you in person on our booth no. 69 or online, 22-26 June 2022!

Saber mais

Evento

Digestive Disease Week® 2022

23.05.2022

We look forward to 2 exciting presentations on day 4 of this year’s DDW!

Saber mais

Comunicado de Imprensa, Indicações

Have difficulty swallowing food?

10.05.2022

Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.

Saber mais

Institucional, Comunicado de Imprensa

Resposta à crise da Ucrânia

18.03.2022

A Dr. Falk Pharma apoia a APOTHEKER HELFEN e.V.

Saber mais

Institucional, Comunicado de Imprensa

O futuro começa aqui

24.02.2022

Planos concluídos para o futuro Falk Campus em Freiburgo

Saber mais

ECCO logo 2022
Evento

ECCO 2022

09.02.2022

Online, from February 16 to 19, 2022. We look forward to seeing you!

Saber mais

Prometheus Logo
Comunicado de Imprensa

Together we advance PR600

03.01.2022

Investigational New Drug Application for PR600 expected in 3Q 2022.

Saber mais